Patents by Inventor William C. Fanslow, III

William C. Fanslow, III has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230235024
    Abstract: The present invention relates to variant Fc-containing molecules, such as antibodies and Fc-fusion molecules, having glycosylation characteristics favorable to large-scale production of therapeutic molecules containing such variant Fc.
    Type: Application
    Filed: July 14, 2022
    Publication date: July 27, 2023
    Applicant: Amgen Inc.
    Inventors: Zhimei DU, Pranhitha REDDY, Randal B. BASS, Feng HE, William C. FANSLOW, III, Yuling ZHANG, Da REN, Randall R. KETCHEM
  • Patent number: 11427627
    Abstract: The present invention relates to variant Fc-containing molecules, such as antibodies and Fc-fusion molecules, having glycosylation characteristics favorable to largescale production of therapeutic molecules containing such variant Fc. Described herein are compositions and methods to improve glycosylation maturation of and to minimize the culture process-dependent effects of Fc-containing molecules, e.g., Fc-fusion molecules and antibodies. Creating single and multiple amino acid substitutions within the Fc domain with the aim to improve high mannose processing and glycosylation maturation.
    Type: Grant
    Filed: September 5, 2014
    Date of Patent: August 30, 2022
    Assignee: Amgen Inc.
    Inventors: Zhimei Du, Pranhitha Reddy, Randal B. Bass, Feng He, William C. Fanslow, III, Yuling Zhang, Da Ren, Randal R. Ketchem
  • Publication number: 20220267446
    Abstract: Provided herein are mixtures of antibodies comprising an anti-hCTLA4 antibody and an anti-hPD1 antibody, polynucleotides encoding such mixtures and host cells containing the polynucleotides, methods of making and using such mixtures, and pharmaceutical compositions comprising such a mixture of antibodies or (a) polynucleotide(s) encoding the mixture.
    Type: Application
    Filed: February 18, 2022
    Publication date: August 25, 2022
    Inventors: Zhi LIU, William C. FANSLOW, III, Wei YAN, David L. TREIBER
  • Patent number: 10465009
    Abstract: The present invention relates to BCMA (B-Cell Maturation Antigen) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases. The present invention also relates to BCMA antibody drug conjugates and uses thereof.
    Type: Grant
    Filed: December 5, 2013
    Date of Patent: November 5, 2019
    Assignee: Amgen Inc.
    Inventors: Richard J. Armitage, Michelle Blake, William C. Fanslow, III, Jason Charles O'Neill, Gunasekaran Kannan, Jiangchun Xu, Mark Edward Tometsko, Zhulun Wang, Athena Sudom
  • Patent number: 10220090
    Abstract: The present invention relates to BCMA (B-Cell Maturation Antigen) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases. The present invention also relates to BCMA antibody drug conjugates.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: March 5, 2019
    Assignee: Amgen Inc.
    Inventors: Richard J. Armitage, Michelle Blake, William C. Fanslow, III, Jason Charles O'Neill, Gunasekaran Kannan, Jiangchun Xu, Mark Edward Tometsko
  • Publication number: 20190008974
    Abstract: The present invention relates to BCMA (B-Cell Maturation Antigen) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases. The present invention also relates to BCMA antibody drug conjugates.
    Type: Application
    Filed: December 11, 2015
    Publication date: January 10, 2019
    Applicant: Amgen Inc.
    Inventors: Richard J. ARMITAGE, Michelle BLAKE, William C. FANSLOW, III, Jason Charles O'NEILL, Gunasekaran KANNAN, Jiangchun XU, Mark Edward TOMETSKO
  • Publication number: 20170165373
    Abstract: The present invention relates to BCMA (B-Cell Maturation Antigen) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases. The present invention also relates to BCMA antibody drug conjugates.
    Type: Application
    Filed: December 11, 2015
    Publication date: June 15, 2017
    Applicant: Amgen Inc.
    Inventors: Richard J. ARMITAGE, Michelle BLAKE, William C. FANSLOW, III, Jason Charles O'NEILL, Gunasekaran KANNAN, Jiangchun XU, Mark Edward TOMETSKO
  • Patent number: 9574008
    Abstract: The present invention relates to CD27L antigen binding proteins, such an antibodies, polynucleotides encoding said CD27l antigen binding proteins, antibody drug conjugate compositions, and methods for diagnosing and treating diseases associated with CD27L expression.
    Type: Grant
    Filed: February 10, 2015
    Date of Patent: February 21, 2017
    Assignee: AMGEN INC.
    Inventors: John M. Delaney, William C. Fanslow, III, Chadwick T. King
  • Publication number: 20160207980
    Abstract: The present invention relates to variant Fc-containing molecules, such as antibodies and Fc-fusion molecules, having glycosylation characteristics favorable to largescale production of therapeutic molecules containing such variant Fc. Described herein are compositions and methods to improve glycosylation maturation of and to minimize the culture process-dependent effects of Fc-containing molecules, e.g., Fc-fusion molecules and antibodies. Creating single and multiple amino acid substitutions within the Fc domain with the aim to improve high mannose processing and glycosylation maturation.
    Type: Application
    Filed: September 5, 2014
    Publication date: July 21, 2016
    Applicant: AMGEN INC.
    Inventors: Zhimei DU, Pranhitha REDDY, Randal B. BASS, Feng HE, William C. FANSLOW, III, Yuling ZHANG, Da REN, Randal R. KETCHEM
  • Patent number: 9243058
    Abstract: The present invention relates to BCMA (B-Cell Maturation Antigen) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases. The present invention also relates to BCMA antibody drug conjugates.
    Type: Grant
    Filed: December 5, 2013
    Date of Patent: January 26, 2016
    Assignee: Amgen, Inc.
    Inventors: Richard J. Armitage, Michelle Blake, William C. Fanslow, III, Jason Charles O'Neill, Gunasekaran Kannan, Jiangchun Xu, Mark Edward Tometsko
  • Publication number: 20150344583
    Abstract: The present invention relates to BCMA (B-Cell Maturation Antigen) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases. The present invention also relates to BCMA antibody drug conjugates and uses thereof.
    Type: Application
    Filed: December 5, 2013
    Publication date: December 3, 2015
    Inventors: Richard J. ARMITAGE, Michelle BLAKE, William C. FANSLOW, III, Jason Charles O'NEILL, Gunasekaran KANNAN, Jiangchun XU, Mark Edward TOMETSKO, Zhulun WANG, Athena SUDOM
  • Publication number: 20150218284
    Abstract: The present invention relates to CD27L antigen binding proteins, such an antibodies, polynucleotides encoding said CD27l antigen binding proteins, antibody drug conjugate compositions, and methods for diagnosing and treating diseases associated with CD27L expression.
    Type: Application
    Filed: February 10, 2015
    Publication date: August 6, 2015
    Inventors: John M. DELANEY, William C. FANSLOW, III, Chadwick T. KING
  • Publication number: 20140161828
    Abstract: The present invention relates to BCMA (B-Cell Maturation Antigen) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases. The present invention also relates to BCMA antibody drug conjugates.
    Type: Application
    Filed: December 5, 2013
    Publication date: June 12, 2014
    Applicant: AMGEN INC.
    Inventors: Richard J. ARMITAGE, Michelle BLAKE, William C. FANSLOW, III, Jason Charles O'NEILL, Gunasekaran KANNAN, Jiangchun XU, Mark Edward TOMETSKO
  • Patent number: 8414895
    Abstract: The present invention provides the TWEAK receptor and methods for identifying and using agonists and antagonists of the TWEAK receptor. In particular, the invention provides methods of screening for agonists and antagonists and for treating diseases or conditions mediated by angiogenesis, such as solid tumors and vascular deficiencies of cardiac or peripheral tissue.
    Type: Grant
    Filed: October 6, 2010
    Date of Patent: April 9, 2013
    Assignee: Immunex Corporation
    Inventors: Kristine M. Kim, Steven R. Wiley, Randal R. Ketchem, William C. Fanslow, III
  • Patent number: 8410252
    Abstract: The invention is directed to purified and isolated novel ULBP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above. ULBP polypeptide can be found on the surface of human B cell lymphomas. Mammalian forms of ULBP polypeptide in isolated or purified forms are provided. In addition, isolated nucleic acids encoding ULBP polypeptides and expression vectors comprising a cDNA encoding ULBP polypeptides are provided. The ULBP polypeptides can be isolated or synthesized and used to prepare antibodies, and in particular monoclonal antibodies, against the polypeptides. The antibodies, in turn, are useful for detecting the presence of ULBP polypeptides in human cell samples, which can be correlated with the existence of a malignant condition in a patient.
    Type: Grant
    Filed: August 24, 2010
    Date of Patent: April 2, 2013
    Assignee: Immunex Corporation
    Inventors: David J Cosman, Jurgen Mullberg, William C Fanslow, III, Marek Z Kubin, Richard J Armitage
  • Publication number: 20110281789
    Abstract: The invention is directed to purified and isolated novel ULBP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above. ULBP polypeptide can be found on the surface of human B cell lymphomas. Mammalian forms of ULBP polypeptide in isolated or purified forms are provided. In addition, isolated nucleic acids encoding ULBP polypeptides and expression vectors comprising a cDNA encoding ULBP polypeptides are provided. The ULBP polypeptides can be isolated or synthesized and used to prepare antibodies, and in particular monoclonal antibodies, against the polypeptides. The antibodies, in turn, are useful for detecting the presence of ULBP polypeptides in human cell samples, which can be correlated with the existence of a malignant condition in a patient.
    Type: Application
    Filed: August 24, 2010
    Publication date: November 17, 2011
    Applicant: IMMUNEX CORPORATION
    Inventors: David J. Cosman, Jurgen Mullberg, William C. Fanslow, III, Marek Kubin, Richard Jeffrey Armitage
  • Publication number: 20110020267
    Abstract: The present invention provides the TWEAK receptor and methods for identifying and using agonists and antagonists of the TWEAK receptor. In particular, the invention provides methods of screening for agonists and antagonists and for treating diseases or conditions mediated by angiogenesis, such as solid tumors and vascular deficiencies of cardiac or peripheral tissue.
    Type: Application
    Filed: October 6, 2010
    Publication date: January 27, 2011
    Inventors: Kristine M. Kim, Steven R. Wiley, Randal R. Ketchem, William C. Fanslow, III
  • Patent number: 7833697
    Abstract: The present invention provides stem cells characterized as having the ability to renew and the ability to give rise to endothelial and/or endothelial-like cells, methods of isolating such stem cells and methods of use thereof. Also provided are progeny cells derived from the stem cells of the invention.
    Type: Grant
    Filed: December 20, 2002
    Date of Patent: November 16, 2010
    Assignee: Immunex Corporation
    Inventors: William C. Fanslow, III, Anne-Marie C. Rousseau, Thomas O. Daniel
  • Patent number: 7829675
    Abstract: The present invention provides the TWEAK receptor and methods for identifying and using agonists and antagonists of the TWEAK receptor. In particular, the invention provides methods of screening for agonists and antagonists and for treating diseases or conditions mediated by angiogenesis, such as solid tumors and vascular deficiencies of cardiac or peripheral tissue.
    Type: Grant
    Filed: January 16, 2009
    Date of Patent: November 9, 2010
    Assignee: Immunex Corporation
    Inventors: Kristine M. Kim, Steven R. Wiley, Randal R. Ketchem, William C. Fanslow, III
  • Patent number: 7807796
    Abstract: The invention is directed to purified and isolated novel ULBP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above. ULBP polypeptide can be found on the surface of human B cell lymphomas. Mammalian forms of ULBP polypeptide in isolated or purified forms are provided. In addition, isolated nucleic acids encoding ULBP polypeptides and expression vectors comprising a cDNA encoding ULBP polypeptides are provided. The ULBP polypeptides can be isolated or synthesized and used to prepare antibodies, and in particular monoclonal antibodies, against the polypeptides. The antibodies, in turn, are useful for detecting the presence of ULBP polypeptides in human cell samples, which can be correlated with the existence of a malignant condition in a patient.
    Type: Grant
    Filed: August 4, 2008
    Date of Patent: October 5, 2010
    Assignee: Immunex Corporation
    Inventors: David J Cosman, Jurgen Mullberg, William C Fanslow, III, Marek Z Kubin, Richard J Armitage